Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1924 1
1929 1
1930 1
1933 1
1939 1
1940 2
1941 4
1943 1
1944 1
1958 2
1959 1
1960 1
1961 1
1962 2
1963 2
1964 2
1965 3
1966 3
1967 5
1968 4
1969 5
1970 8
1971 5
1972 11
1973 12
1974 15
1975 14
1976 17
1977 13
1978 13
1979 14
1980 12
1981 14
1982 15
1983 13
1984 18
1985 16
1986 18
1987 18
1988 12
1989 29
1990 25
1991 17
1992 17
1993 14
1994 21
1995 20
1996 24
1997 31
1998 14
1999 18
2000 20
2001 29
2002 20
2003 25
2004 31
2005 47
2006 39
2007 39
2008 59
2009 70
2010 69
2011 86
2012 121
2013 129
2014 140
2015 132
2016 137
2017 137
2018 139
2019 163
2020 199
2021 233
2022 245
2023 212
2024 239
2025 193
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,106 results

Results by year

Filters applied: . Clear all
Page 1
mRNA vaccines: a new era in vaccine development.
Chandra S, Wilson JC, Good D, Wei MQ. Chandra S, et al. Oncol Res. 2024 Sep 18;32(10):1543-1564. doi: 10.32604/or.2024.043987. eCollection 2024. Oncol Res. 2024. PMID: 39308511 Free PMC article. Review.
Microplastics in water: Occurrence, fate and removal.
Chandra S, Walsh KB. Chandra S, et al. J Contam Hydrol. 2024 May;264:104360. doi: 10.1016/j.jconhyd.2024.104360. Epub 2024 May 4. J Contam Hydrol. 2024. PMID: 38729026 Free article. Review.
Acute kidney injury in patients treated with immune checkpoint inhibitors.
Gupta S, Short SAP, Sise ME, Prosek JM, Madhavan SM, Soler MJ, Ostermann M, Herrmann SM, Abudayyeh A, Anand S, Glezerman I, Motwani SS, Murakami N, Wanchoo R, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, Seigneux S, Campedel L, Kitchlu A, Shin DS, Rangarajan S, Deshpande P, Coppock G, Eijgelsheim M, Seethapathy H, Lee MD, Strohbehn IA, Owen DH, Husain M, Garcia-Carro C, Bermejo S, Lumlertgul N, Seylanova N, Flanders L, Isik B, Mamlouk O, Lin JS, Garcia P, Kaghazchi A, Khanin Y, Kansal SK, Wauters E, Chandra S, Schmidt-Ott KM, Hsu RK, Tio MC, Sarvode Mothi S, Singh H, Schrag D, Jhaveri KD, Reynolds KL, Cortazar FB, Leaf DE; ICPi-AKI Consortium Investigators. Gupta S, et al. Among authors: chandra s. J Immunother Cancer. 2021 Oct;9(10):e003467. doi: 10.1136/jitc-2021-003467. J Immunother Cancer. 2021. PMID: 34625513 Free PMC article.
Author Reply Re: Nerli RB, Ghagane SC, Rangrez S, Chandra S, Thakur ML, Gomella L. Detection of bladder cancer using voided urine sample and by targeting genomic VPAC receptors. Indian J Urol 2021;37:345-9.
Nerli RB, Ghagane SC, Rangrez SS, Chandra S, Thakur ML, Gomella L. Nerli RB, et al. Among authors: chandra s. Indian J Urol. 2022 Jan-Mar;38(1):78-79. doi: 10.4103/iju.iju_462_21. Epub 2022 Jan 1. Indian J Urol. 2022. PMID: 35136304 Free PMC article. No abstract available.
Preexisting Skin-Resident CD8 and γδ T-cell Circuits Mediate Immune Response in Merkel Cell Carcinoma and Predict Immunotherapy Efficacy.
Reinstein ZZ, Zhang Y, Ospina OE, Nichols MD, Chu VA, Pulido AM, Prieto K, Nguyen JV, Yin R, Moran Segura C, Usman A, Sell B, Ng S, de la Iglesia JV, Chandra S, Sosman JA, Cho RJ, Cheng JB, Ivanova E, Koralov SB, Slebos RJC, Chung CH, Khushalani NI, Messina JL, Sarnaik AA, Zager JS, Sondak VK, Vaske C, Kim S, Brohl AS, Mi X, Pierce BG, Wang X, Fridley BL, Tsai KY, Choi J. Reinstein ZZ, et al. Among authors: chandra s. Cancer Discov. 2024 Sep 4;14(9):1631-1652. doi: 10.1158/2159-8290.CD-23-0798. Cancer Discov. 2024. PMID: 39058036 Free PMC article.
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.
Hughes BGM, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, Grob JJ, Lewis KD, Ansstas G, Day F, Ladwa R, Stein BN, Muñoz Couselo E, Meier F, Hauschild A, Schadendorf D, Basset-Seguin N, Modi B, Dalac-Rat S, Dunn LA, Flatz L, Mortier L, Guégan S, Heinzerling LM, Mehnert JM, Trabelsi S, Soria-Rivas A, Stratigos AJ, Ulrich C, Wong DJ, Beylot-Barry M, Bossi P, Bugés Sánchez C, Chandra S, Robert C, Russell JS, Silk AW, Booth J, Yoo SY, Seebach F, Lowy I, Fury MG, Rischin D. Hughes BGM, et al. Among authors: chandra s. J Am Acad Dermatol. 2025 Jan;92(1):68-77. doi: 10.1016/j.jaad.2024.06.108. Epub 2024 Sep 7. J Am Acad Dermatol. 2025. PMID: 39245360 Clinical Trial.
3,106 results